TABLE 3

Patient follow-up and outcomes

0 years1 year2 years3 years
Patients1301138050
Pulmonary function tests
 FVC mL2742±8212738±8072745±8542658±860
 FVC %82.6±17.585.2±19.385.8±21.281.7±19.5
 TLC mL4744±11834526±12124397±11794399±1152
 TLC %78.9±15.776.3±15.674.8±14.773.1±15.5
DLCO %50.8±16.852.9±17.853.6±17.452.0±15.9
KCO %75.4±20.778.7±23.484.0±27.682.9±20.8
 6MWD m429±88.7427±104.1433±94.1437±94.2
Respiratory infection pattern (≥2 respiratory infections per year in ≥2 years of the 3 years of follow-up)23 (17.7)
Acute exacerbation (hospital admission)28 (21.5)
Antifibrotic stop or switch due to adverse effects44 (33.8)
Antifibrotic stop or switch due to IPF progression6 (4.6)
Progression-free survival55 (42.3)
 FVC progression (decrease ≥10%)42 (32.3)
DLCO progression (decrease ≥15%)20 (15.4)
 Lung transplant by IPF progression12 (9.2)
 Death by IPF progression25 (19.2)

Data are presented as n, mean±sd or n (%). FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; 6MWD: 6-min walk distance; IPF: idiopathic pulmonary fibrosis.